1. Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and “BRCA-Like” Status, in Both Blood and Tumour DNA
   Sarah L. Daniels et al, 2016, PLoS ONE CrossRef
2. CDH22 hypermethylation is an independent prognostic biomarker in breast cancer
   Esperanza Martín-Sánchez et al, 2017, Clin Epigenet CrossRef
3. Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients
   Melanie Spitzwieser et al, 2017, BMC Cancer CrossRef
4. BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer
   William Jacot et al, 2020, Cancers CrossRef
5. CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer
   Esperanza Martín-Sánchez et al, 2017, Oncotarget CrossRef
6. Prognostic epigenetics
   Adriana Fodor et al, 2021 CrossRef
7. Trojan-Like Peptide Drug Conjugate Design and Construction for Application in Treatment of Triple-Negative Breast Cancer
   Chuanguang Xiao et al, 2021, j biomed nanotechnol CrossRef
8. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status
   Yuwei Wang et al, 2024, BMC Med CrossRef
9. Prognostic Effects of RASSF1A, BRCA1, APC, and p16 Promoter Methylation in Ovarian Cancer: A Meta-Analysis
   Cheng Chen et al, 2024, Gynecol Obstet Invest CrossRef